^
Association details:
| Biomarker: | TENM4-NRG1 fusion |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | seribantumab (MM-121) (HER3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with oncogenic NRG1 fusions
Published date:
04/06/2021
Excerpt:
Seribantumab inhibited NRG1-stimulated growth of MCF-7 cells and growth of patient-derived breast (MDA-MB-175-VII, DOC4-NRG1)...cancer cells harboring NRG1 fusions....In addition, seribantumab inhibited growth of isogenic HBEC cells expressing a CD74-NRG1 fusion (HBECp53-CD74-NRG1) and induced apoptosis in MDA-MB-175-VII and LUAD-0061AS3 cells.
DOI:
10.1158/1078-0432.CCR-20-3605
